Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
Status:
Completed
Trial end date:
2020-12-05
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks
and duration of administration for 1 year in patients with high-risk essential
thrombocythemia.